OBIO
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Orchestra BioMed Holdings, Inc. (OBIO) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (2.9) | D+ (1.7) | C+ (2.8) | A (4.2) | A+ (5.0) | B (3.3) |
| 2026-11-06 | B- (3.0) | D+ (1.6) | C (2.4) | A (4.3) | A+ (5.0) | B (3.2) |
| 2026-10-30 | B- (3.0) | D+ (1.6) | C (2.5) | A (4.5) | A+ (5.0) | B (3.3) |
| 2026-10-23 | B- (3.0) | D+ (1.6) | C (2.4) | A (4.2) | A+ (5.0) | B (3.2) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe